[Edaily Reporter NA EUN-KYUNG ] “I believe EarlyTec-B has the potential to largely replace existing bladder cancer tumor marker tests. It could also serve as a new testing option for patients with hematuria who are hesitant about undergoing cystoscopy.”
Dr. Jang Jin-seok, Director of Jamsil Seoul Urology Clinic, recently met with Pharm E-Daily at the clinic in Songpa-gu, Seoul, and offered this assessment regarding the practical application of the urine-based early-stage bladder cancer diagnostic test “EarlyTec-B” ( Genomictree Inc.(228760) ) in clinical settings.
During an interview with E-Daily at Jamsil Seoul Urology Clinic in Songpa-gu, Seoul, Director Jang Jin-seok used a Namsung urogenital anatomy model to explain the process by which a cystoscope is inserted through the urethra into the bladder. (Photo: E-Daily reporter NA EUN-KYUNG )
Hematuria is far more common than one might think. According to Dr. Jang, microscopic hematuria is detected in urine tests for 2 to 3 out of every 10 patients who visit a urology clinic. He explained that on the day of the interview alone, nearly 10 patients with hematuria had visited the clinic by mid-morning. In addition to patients who visit the hospital specifically because of hematuria, there are also a significant number of cases where hematuria is incidentally discovered during a urinalysis in patients who came in for other reasons, such as benign prostatic hyperplasia or urinary dysfunction.
The challenge lies in how to efficiently identify patients at risk for bladder cancer among those presenting with hematuria. While hematuria can result from various causes—such as urinary tract infections, kidney stones, or physical activity—it can also be a sign of urinary tract tumors, including bladder, kidney, and prostate cancers. Director Jang explained that, in his experience, the rate at which bladder cancer is actually diagnosed among patients with hematuria is approximately 1 percent. Ultimately, the key is to identify the small number of bladder cancer patients among the large number of patients with hematuria without missing any.
While it is necessary to screen a significant number of patients with hematuria for the possibility of bladder cancer, cystoscopy remains a burdensome procedure. Urine-based molecular diagnostic tests have stepped in to fill this gap. Last July, Genomictree Inc.’s “EarlyTec-B”—a molecular diagnostic test that assesses bladder cancer risk by measuring the methylation of the PENK gene in urine—received conditional approval under the New Medical Technology Evaluation system, paving the way for its use as a non-insured test in South Korea’s healthcare system. However, its use is currently limited to general hospitals and tertiary general hospitals.
Hematuria Is Common, but Endoscopy Is a Burden
Hematuria is divided into gross hematuria, where blood is visible to the naked eye, and microscopic hematuria, where red blood cells are detected only through a urinalysis and are not visible to the naked eye. When hematuria is detected, a urinalysis is first performed to check for inflammation, and depending on the need, the cause is investigated through kidney and bladder ultrasounds, computed tomography (CT) scans, and cystoscopy.
The problem is that patients often do not take hematuria seriously. Hematuria does not necessarily mean the urine is a vivid red color. Some patients simply notice that their urine is darker or cloudier than usual and dismiss it as a result of drinking less water or taking vitamins.
Dr. Jang stated, “Even urine that is just slightly darker in color can be hematuria,” adding, “Caution is needed because tumors in the urinary tract often present only with hematuria and no pain.” This is because there have been cases where patients did not seek medical attention even after hematuria repeatedly appeared and disappeared, only to have bladder cancer discovered at a significantly advanced stage.
Dr. Jang graduated from Seoul National University College of Medicine and completed his graduate studies at the Seoul National University Graduate School of Medicine. After completing his internship and residency at Seoul National University Hospital, he became a board-certified urologist. He currently serves as the director of Jamsil Seoul Urology Clinic and is an active member of the American Urological Association (AUA).
An image of a flexible cystoscope (left) and a schematic diagram illustrating the examination process (right). Cystoscopy is a procedure in which an endoscope is inserted through the urethra to directly examine the interior of the bladder. (Source: Jamsil Seoul Urology Clinic, Korean Association of Urologists)
Even for patients who visit the hospital out of concern for bladder cancer, a cystoscopy presents a significant psychological barrier. This is due to the discomfort, fear, and embarrassment associated with the procedure itself, which involves inserting an endoscope through the urethra.
Dr. Jang said, “At our hospital, we use a flexible endoscope, which causes relatively less discomfort, but it is true that patients still feel a great deal of anxiety about cystoscopy.” He added, “Therefore, for patients who do not necessarily need an endoscopy, we often explain that other tests can be performed first.”
He assessed that EarlyTec-B could help determine whether a cystoscopy is necessary. For patients with a bladder cancer risk above a certain threshold—such as those with recurrent microscopic hematuria—who find it difficult or are reluctant to undergo a cystoscopy immediately, the approach is to first perform a urine-based test; if abnormal results are found, they proceed to additional tests such as cystoscopy and CT scans.
Is it a viable alternative to existing tumor markers?
There is already significant demand for the type of testing EarlyTec-B is set to enter. Director Jang explained that, upon reviewing his hospital’s medical records prior to the interview, he found that the number of bladder cancer-related tumor marker tests performed in a single month exceeded 100. This represents approximately 20–30% of patients with confirmed hematuria.
Currently, the leading urine-based tests are NMP22 and urine cytology. NMP22 measures bladder cancer-associated proteins in urine, while urine cytology examines the morphology of cells shed into the urine to assess the likelihood of cancer.
However, he explained that existing tests have limitations in accuracy, so it is common to perform both tests together or at different times. In contrast, EarlyTec-B demonstrates relatively high diagnostic performance, particularly in terms of negative predictive value, and is therefore considered likely to replace existing tests to a significant extent.
“Rather than duplicating multiple tests to determine the same thing, wouldn’t it be better to replace them with a single test?” he said, adding, “I believe EarlyTec-B can play a significant role.”
However, he made it clear that it is not a test that replaces cystoscopy itself. If EarlyTec-B reveals abnormal findings, follow-up tests such as CT scans and cystoscopy are necessary. Director Jang predicted that urine-based molecular diagnostics and cystoscopy will continue to develop in a complementary rather than a substitute relationship.
When asked about the key factors for the widespread adoption of EarlyTec-B, he cited price and cost-effectiveness. He explained that EarlyTec-B must establish a price point that is acceptable to patients, falling between existing tumor marker tests and cystoscopy. He predicted that if health insurance coverage is extended in the future, reducing the out-of-pocket cost for patients, the scope of the test’s use could expand significantly.
Director Jang believes that if appropriate insurance reimbursement rates are applied, more healthcare providers will choose EarlyTec-B over existing urine-based tumor marker tests.
The scope of use by medical institutions is another factor that will determine future adoption. Currently, due to a moratorium on the evaluation of new medical technologies, EarlyTec-B is restricted to general hospitals and higher-level facilities, meaning it cannot be used at primary care clinics.
Director Jang, however, believes that EarlyTec-B would be particularly valuable at primary care urology clinics or health screening centers that lack cystoscopy facilities. According to Director Jang’s estimates, primary care urology clinics equipped with cystoscopy equipment account for only about 20–30% of the total. This is because these facilities play a crucial role in screening patients who require further diagnostic testing based on urine test results. If EarlyTec-B remains available only at general hospitals or higher-level facilities, as is currently the case, patients who first notice hematuria at a primary care clinic would still have to revisit a large hospital just for a single urine test.
Director Jang emphasized, “It is deeply regrettable that primary care urology clinics—which are the first point of contact for patients with hematuria—are unable to utilize this test. Although the test has been approved by the Ministry of Food and Drug Safety, restricting its use to general hospitals and above is out of step with actual clinical practice. I hope the scope of use will be expanded as soon as possible so that primary care clinics can perform the test proactively and refer patients to large hospitals when necessary.”
As the U.S.-Iran war—which erupted in late February following large-scale military operations by the U.S. and Israel against Iran—drags on, concerns are growing over its impact on the Korean economy a…
Daesang ( Daesang(001680)) is donating Cheongjeonwon food sets worth 100 million won to help vulnerable residents in Jongno-gu, Seoul, get through the winter.
Daesang’s Head of ESG Management, Kim …
#Graphy Inc., in partnership with dental medical device company Ray Co., Ltd., unveiled a digital dental solution that covers everything from diagnosis to the fabrication of orthodontic appliances. Fo…